STOCK TITAN

Woodline Partners (PLRX) discloses 3.3% beneficial stake in Pliant

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Woodline Partners LP filed an amended Schedule 13G/A reporting its beneficial ownership of Pliant Therapeutics common stock. Woodline reports beneficial ownership of 2,026,191 shares, representing 3.3% of the outstanding common stock, based on 61,449,385 shares outstanding as of November 1, 2025.

The shares are held through Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, with sole voting and dispositive power over all reported shares. Woodline certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What ownership stake does Woodline Partners report in Pliant Therapeutics (PLRX)?

Woodline Partners reports beneficial ownership of 2,026,191 shares of Pliant Therapeutics common stock. This equals 3.3% of the company’s outstanding shares, based on 61,449,385 shares outstanding as of November 1, 2025, as cited in the filing.

What type of SEC filing did Woodline Partners submit for Pliant Therapeutics (PLRX)?

Woodline Partners submitted an amended Schedule 13G/A for Pliant Therapeutics. This form is used to report passive beneficial ownership of more than 5%, or amendments as holdings change, and is generally associated with investors not seeking control of the company.

How much voting power does Woodline Partners have over Pliant Therapeutics (PLRX) shares?

Woodline Partners reports sole voting power over 2,026,191 shares of Pliant Therapeutics common stock. It also reports sole dispositive power over the same number of shares, with no shared voting or shared dispositive power indicated in the filing.

Who actually holds the Pliant Therapeutics (PLRX) shares reported by Woodline Partners?

The shares are directly held by Woodline Master Fund LP. Woodline Partners LP, a Delaware limited partnership, is the investment adviser to this fund and reports beneficial ownership with respect to these Pliant Therapeutics common shares in the Schedule 13G/A.

Does Woodline Partners seek to influence control of Pliant Therapeutics (PLRX)?

Woodline Partners certifies the securities were acquired and are held in the ordinary course of business. The filing states they were not acquired and are not held for the purpose of changing or influencing control of Pliant Therapeutics, consistent with passive ownership.

What date does the Woodline Partners ownership report for Pliant Therapeutics (PLRX) relate to?

The Schedule 13G/A lists December 31, 2025 as the date of the event requiring the filing. The ownership percentage is calculated using Pliant’s 61,449,385 shares outstanding as of November 1, 2025, as reported in the company’s Form 10-Q.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Woodline Partners LP
Signature:/s/ Erin Mullen
Name/Title:Erin Mullen, General Counsel & Chief Compliance Officer
Date:02/17/2026